ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,172,814 | -6.3% | 9,603 | -20.8% | 0.01% | 0.0% |
| Q3 2022 | $1,252,000 | +417.4% | 12,124 | +366.7% | 0.01% | +600.0% |
| Q2 2022 | $242,000 | +1513.3% | 2,598 | +2261.8% | 0.00% | – |
| Q4 2021 | $15,000 | -31.8% | 110 | -20.3% | 0.00% | – |
| Q3 2021 | $22,000 | -74.1% | 138 | -78.6% | 0.00% | -100.0% |
| Q2 2021 | $85,000 | +123.7% | 646 | +122.0% | 0.00% | – |
| Q1 2021 | $38,000 | -74.1% | 291 | -67.0% | 0.00% | -100.0% |
| Q4 2020 | $147,000 | +1370.0% | 881 | +857.6% | 0.00% | – |
| Q1 2020 | $10,000 | -99.0% | 92 | -98.9% | 0.00% | -100.0% |
| Q1 2019 | $1,002,000 | +254.1% | 8,517 | +88.3% | 0.03% | +146.2% |
| Q4 2018 | $283,000 | – | 4,522 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |